首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull.
【24h】

Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull.

机译:使用颅骨的非侵入性固定术,单独行低分形立体定向放射疗法而无全脑照射的单发和少脑转移患者。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) using noninvasive fixation of the skull on solitary or oligo brain metastatic patients as an alternative to stereotactic radiosurgery (SRS) using invasive fixation.The subjects were 87 patients who had 4 or fewer brain metastases (50 solitary, 37 oligometastases). Treatment was conducted on 159 metastases by using a linac-based stereotactic system. The median isocentric dose was 35 Gy in 4 fractions. Whole-brain irradiation was not applied as an initial treatment. For the salvage treatment of metachronous brain metastases, repeat HSRT or whole-brain irradiation was applied.The actuarial 1-year local tumor control rate was 81%. Treatment-related complications were observed in 4 patients in the early period (<3 months) and in 2 patients in the late period. The median survival period was 8.7 months. Metachronous brain metastases occurred in 30 patients, and none of the 18 patients who were eligible for salvage HSRT refused to receive it again.Hypofractionated stereotactic radiotherapy achieved tumor control and survival equivalent to those of SRS reported in the literature. The results suggested that HSRT could be an alternative for solitary or oligo brain metastatic patients with less toxicity and less invasiveness compared to SRS.
机译:评估使用无创颅骨固定术对单发或少发性脑转移患者进行替代性立体定向放射外科手术(SRS)的替代方法,以低分形立体定向放射疗法(HSRT)的疗效和毒性,研究对象为87例大脑少于4个的患者转移(单发50例,低转移37例)。使用基于直线加速器的立体定向系统对159个转移灶进行了治疗。中位等中心剂量为35 Gy,分为4个部分。不进行全脑照射作为初始治疗。为了挽救异时性脑转移瘤,应用重复HSRT或全脑放疗。精算1年局部肿瘤控制率为81%。在早期(<3个月)中有4例患者出现了与治疗相关的并发症,在晚期时有2例患者出现了与治疗相关的并发症。中位生存期为8.7个月。 30例患者发生了异时脑转移,18例符合条件的挽救性HSRT患者均未拒绝再次接受转移治疗。超分割立体定向放射疗法可达到与文献报道的SRS相当的肿瘤控制和生存率。结果表明,与SRS相比,HSRT可以替代单发或少发性脑转移患者,且毒性小,侵袭性小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号